<GlossaryTerm id="CDR0000575396"><TermName>nilotinib</TermName><TermPronunciation>(ny-LOH-tih-nib)</TermPronunciation><TermDefinition><DefinitionText>A drug used to treat certain types of chronic myelogenous leukemia that are Philadelphia chromosome positive. It is also being studied in the treatment of other types of cancer. Nilotinib blocks BCR::ABL1 and other proteins, which may help keep cancer cells from growing. It is a type of tyrosine kinase inhibitor. Also called Tasigna.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000721206" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;nilotinib&quot;" language="en" id="_5"/><MediaLink ref="CDR0000721205" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;nilotinib&quot;" language="es" id="_6"/><SpanishTermName>nilotinib</SpanishTermName><SpanishTermDefinition><DefinitionText>Medicamento que
se usa para el tratamiento de ciertos tipos de leucemia mielógena
crónica positivos para el cromosoma Filadelfia. También, está en estudio para el tratamiento de otros tipos de cáncer.  El nilotinib bloquea BCR::ABL1 y otras proteínas, lo que quizás ayude a impedir la multiplicación de células cancerosas. Es un tipo de inhibidor de tirosina–cinasas. También se llama Tasigna.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2007-12-07</DateFirstPublished><DateLastModified>2024-10-29</DateLastModified><RelatedInformation><RelatedDrugSummaryRef UseWith="en" href="CDR0000575327" url="/about-cancer/treatment/drugs/nilotinib">Nilotinib</RelatedDrugSummaryRef></RelatedInformation></GlossaryTerm>
